acquired TTP but with an atypical presentation. A subopti- mal response to PEX, defined as the absence of a steadily declining lactate dehydrogenase level and an increase in the platelet count after 4–5 days of daily PEX in the context of ADAMTS13 >10%, would lead us to consider therapy with eculizumab over intensified PEX or immune-based therapy as might be considered in TTP.
Acknowledgements
SRC and HMW designed the study, performed the research, analysed the data, and wrote the paper. SY performed the research and analysed the data.
Spero R. Cataland
1Shangbin Yang
2Haifeng M. Wu
21